ASCO 2019 Meet & Greet

Article

Come visit us at our booth in the Exhibit Hall (Booth #18104) at the 2019 ASCO Annual Meeting.

Check back often to see when some of our Editors-in-Chief, Board Members, and Cover Authors will be at our booth (Booth #18104):

Julie Vose, MD, MBA
Monday, June 3, 1:30 pm

Recent Videos
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content